Protagonist Therapeutics (PTGX) Retained Earnings (2015 - 2026)

Protagonist Therapeutics has reported Retained Earnings for 12 years, with the latest figure at -$269000.0 in Q1 2026.

• Quarterly Retained Earnings fell 416.47% year-over-year to -$269000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$269000.0 (down 416.47% YoY) and the FY2025 annual result came in at $641000.0, up 100.19% from the prior year.
• Retained Earnings fell to -$269000.0 in Q1 2026 per PTGX's latest filing, from $641000.0 in the prior quarter.
• Over five years, Retained Earnings peaked at $641000.0 in Q4 2025 and troughed at -$615.7 million in Q4 2023.
• A 5-year average of -$291.4 million and a median of -$408.4 million in 2024 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings slumped 277664.71% in 2024, then jumped 100.19% in 2025.
• Over 5 years, Retained Earnings stood at -$536.8 million in 2022, then fell by 14.71% to -$615.7 million in 2023, then soared by 44.69% to -$340.5 million in 2024, then surged by 100.19% to $641000.0 in 2025, then sank by 141.97% to -$269000.0 in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$269000.0, $641000.0, and -$426.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.